指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

ISCCM 立场声明:重症监护病房侵袭性真菌感染的管理

ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit.
指南 / 共识 · Indian J Crit Care Med · 2024-08-10
一句话结论ISCCM 发布立场声明,为 ICU 中免疫功能正常及非中性粒细胞减少患者侵袭性真菌感染的诊断与抗真菌治疗优化提供实践要点。

该立场声明由印度重症监护医学会(ISCCM)组织全国重症医学专家制定,针对 ICU 中因广谱抗生素、免疫抑制剂使用及留置导管导致侵袭性真菌感染(IFI)日益增多的问题,系统更新了流行病学、危险因素、诊断路径、抗真菌启动策略、包括部位特异性感染在内的治疗干预及治疗药物监测的证据。委员会广泛检索电子数据库及国际指南并交叉引用,经多次会议讨论形成实践要点,最终由该领域专家审核。声明聚焦免疫功能正常及非中性粒细胞减少的 ICU 患者,旨在帮助临床医生优化疑似或确诊真菌感染危重患者的管理。

要点

  • ICU 中侵袭性真菌感染因广谱抗生素、免疫抑制剂使用及留置导管频繁而日益增多,及时诊断对改善预后至关重要但存在挑战。
  • 该立场声明针对免疫功能正常及非中性粒细胞减少的 ICU 患者,而非仅中性粒细胞减少人群。
  • 声明涵盖危险因素、合理诊断路径、抗真菌启动策略、部位特异性感染治疗及治疗药物监测等实践要点。
  • 实践要点旨在帮助重症医学工作者理顺疑似或确诊真菌感染危重患者的诊断与治疗策略。

适用人群与场景

  • ICU 中免疫功能正常及非中性粒细胞减少的成人患者,疑似或确诊侵袭性真菌感染。

研究设计与关键结果

  • 制定机构:印度重症监护医学会(ISCCM);方法:成立全国重症医学专家委员会,分工负责特定真菌感染及抗真菌治疗领域,广泛检索电子数据库及国际指南并交叉引用,经多次会议讨论形成立场声明,初稿经全体成员共识并由该领域专家审核。
  • 更新了 ICU 侵袭性真菌感染管理的现有证据,并在各亚标题下制定实践要点,涵盖诊断与治疗策略及部位特异性感染、治疗药物监测等附加细节。

证据类型、等级与局限

  • 证据类型:学会立场声明(指南/共识);证据等级或推荐强度:原文未给出具体分级标签。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 该立场声明旨在指导临床医生优化 ICU 中疑似或确诊真菌感染危重患者的管理,实践要点可用于理顺诊断与治疗策略。
  • 声明重点关注免疫功能正常及非中性粒细胞减少的 ICU 患者,实践要点应在此类人群中应用。

指南或共识出处

  • ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit. Indian J Crit Care Med 2024;28(S2):S20-S41.

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Invasive fungal infections (IFI) in the intensive care unit (ICU) are an emerging problem owing to the use of broad-spectrum antibiotics, immunosuppressive agents, and frequency of indwelling catheters. Timely diagnosis which is imperative to improve outcomes can be challenging. This position statement is aimed at understanding risk factors, providing a rational diagnostic approach, and guiding clinicians to optimize antifungal therapy.

OBJECTIVES: To update evidence on epidemiology, risk factors, diagnostic approach, antifungal initiation strategy, therapeutic interventions including site-specific infections and role of therapeutic drug monitoring in IFI in ICU and focus on some practice points relevant to these domains.

METHODOLOGY: A committee comprising critical care specialists across the country was formed and specific aspects of fungal infections and antifungal treatment were assigned to each member. They extensively reviewed the literature including the electronic databases and the international guidelines and cross-references. The information was shared and discussed over several meetings and position statements were framed to ensure their reliability and relevance in critical practice. The draft document was prepared after obtaining inputs and consensus from all the members and was reviewed by an expert in this field.

RESULTS: The existing evidence on the management of IFI was updated and practice points were prepared under each subheading to enable critical care practitioners to streamline diagnosis and treatment strategies for patients in the ICU with additional detail on site-specific infections therapeutic drug monitoring.

CONCLUSION: This position statement attempts to address the management of IFI in immunocompetent and non-neutropenic ICU patients. The practice points should guide in optimization of the management of critically ill patients with suspected or proven fungal infections.

HOW TO CITE THIS ARTICLE: Bhattacharya PK, Chakrabarti A, Sinha S, Pande R, Gupta S, Kumar AAK, et al. ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit. Indian J Crit Care Med 2024;28(S2):S20-S41.

来源:Indian J Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bhattacharya PK, Chakrabarti A, Sinha S, et al. ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit. Indian J Crit Care Med. 2024. PMID: 39234228. doi:10.5005/jp-journals-10071-24747

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。